Cardiovascular RisksEAPC-CVRISK 20NCT07603869
Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026
An observational study of Cardiovascular Risks, run by European Society of Cardiology at 1 site in Slovenia.
Trial summary
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Risks
- What is being tested?
- Questionnaire and Physical Exam and blood draw
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 511 participants
- Where
- 1 siteSlovenia
- Study dates
- 23 Apr 2026to 24 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All adults attendees (including healthcare professional) attending the EAPC Congress 2026 from 23 and 24 April in Ljubljana
Who may be able to join
- All attendees including healthcare professionals (doctors, nurses, etc.) attending the EAPC Congress 2026 from 23 to 24 April 2026
- Subjects who declare that they are able to understand and give informed consent in English
Who cannot join
- Subjects not willing to provide his/her consent to participate in the study.
- Subjects who are not suitable candidates for blood extraction.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Cross-Sectional Assessment of Cardiovascular Risk Among EAPC Congress 2026 Participants
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens.
In line with this call for public health diagnosis of CV health, the ESC, through the European Association of Preventive Cardiology (EAPC), is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Preventive Cardiology Congress 2026 from 23-24 April 2026 in Ljubljana, Slovenia.
The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.
- Conditions
- Cardiovascular Risks
- Being tested
- Questionnaire and Physical Exam, blood draw
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Questionnaire and Physical ExamBehavioural
Questionnaire EQ-5D-5L with some lifestyle habits and medical history
Questionnaire and Physical ExamBehavioural
Waist circumference and blood pressure measurements
blood drawBiological
Blood draw
What is being measured
The primary outcome is the main question the study is designed to answer.
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline
Measured: Baseline
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baseline
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start23 Apr 2026
- Primary completion24 Apr 2026
- Study completion24 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular RisksStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 511 participants (actual)
Sponsor and investigators
- Lead sponsor
- European Society of Cardiology
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Zlatko Fras, Study chair, Division of Medicine, Centre for Preventive Cardiology, University Medical Centre, SloveniaTim Kambič, Study chair, Department of Medical Sciences in Sport and Exercise, Faculty of Sport, University of Ljubljana, Slovenia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07603869
- Sponsor's protocol ID
- EAPC-CVRISK 2026
- Acronym
- EAPC-CVRISK 20
- Status last verified
- Aug 2026
- First submitted
- 18 May 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-Sectional Assessment of Cardiovascular Risk Among EAPC Congress 2026 Participants
- ClinicalTrials.gov ID
- NCT07603869
- Acronym / sponsor ID
- EAPC-CVRISK 20 / EAPC-CVRISK 2026
- Conditions
- Cardiovascular Risks
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 511 participants (actual)
- Lead sponsor
- European Society of CardiologyResearch network
- Study start
- 23 Apr 2026 (actual)
- Primary completion
- 24 Apr 2026 (actual)
- Study completion
- 24 Apr 2026 (actual)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens.
In line with this call for public health diagnosis of CV health, the ESC, through the European Association of Preventive Cardiology (EAPC), is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Preventive Cardiology Congress 2026 from 23-24 April 2026 in Ljubljana, Slovenia.
The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All adults attendees (including healthcare professional) attending the EAPC Congress 2026 from 23 and 24 April in Ljubljana
Key inclusion criteria (2 listed)
- All attendees including healthcare professionals (doctors, nurses, etc.) attending the EAPC Congress 2026 from 23 to 24 April 2026
- Subjects who declare that they are able to understand and give informed consent in English
Key exclusion criteria (2 listed)
- Subjects not willing to provide his/her consent to participate in the study.
- Subjects who are not suitable candidates for blood extraction.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Questionnaire and Physical ExamQuestionnaire EQ-5D-5L with some lifestyle habits and medical history | Behavioural | – |
| Questionnaire and Physical ExamWaist circumference and blood pressure measurements | Behavioural | – |
| blood drawBlood draw | Biological | – |
Primary outcome
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline
Time frame: Baseline
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baseline
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
Related trials for Cardiovascular Risks
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Decision Support for Chemoprevention
Breast Cancer
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zlatko Fras study chair
Division of Medicine, Centre for Preventive Cardiology, University Medical Centre, Slovenia
Tim Kambič study chair
Department of Medical Sciences in Sport and Exercise, Faculty of Sport, University of Ljubljana, Slovenia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Risks, run by European Society of Cardiology at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.